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Abstract
Curcumin derived from turmeric is well documented for its anti-carcinogenic, antioxidant and anti-inflammatory properties. Recent studies
show that curcumin also possesses neuroprotective and cognitive-enhancing properties that may help delay or prevent neurodegenerative
diseases, including Alzheimer’s disease (AD). Currently, clinical diagnosis of AD is onerous, and it is primarily based on the exclusion of other
causes of dementia. In addition, phase III clinical trials of potential treatments have mostly failed, leaving disease-modifying interventions
elusive. AD can be characterised neuropathologically by the deposition of extracellular β amyloid (Aβ) plaques and intracellular accumulation
of tau-containing neurofibrillary tangles. Disruptions in Aβ metabolism/clearance contribute to AD pathogenesis. In vitro studies have shown
that Aβ metabolism is altered by curcumin, and animal studies report that curcumin may influence brain function and the development of
dementia, because of its antioxidant and anti-inflammatory properties, as well as its ability to influence Aβ metabolism. However, clinical
studies of curcumin have revealed limited effects to date, most likely because of curcumin’s relatively low solubility and bioavailability, and
because of selection of cohorts with diagnosed AD, in whom there is already major neuropathology. However, the fresh approach of targeting
early AD pathology (by treating healthy, pre-clinical and mild cognitive impairment-stage cohorts) combined with new curcumin formulations
that increase bioavailability is renewing optimism concerning curcumin-based therapy. The aim of this paper is to review the current evidence
supporting an association between curcumin and modulation of AD pathology, including in vitro and in vivo studies. We also review the use
of curcumin in emerging retinal imaging technology, as a fluorochrome for AD diagnostics.
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With the ageing of many populations worldwide, it is predicted
that over the next few decades there will be a marked increase
in the number of people with dementia. Current estimations
show that 35·6 million people worldwide have dementia, which
is predicted to more than triple to 115 million by 2050(1). Of all
the dementia sub-types, Alzheimer’s disease (AD) is the
most common. AD is a neurodegenerative disease, which is
characterised clinically by the progressive loss of memory and
cognitive functioning. Major pathological features of an AD
brain include the accumulation of extracellular plaques and
fibrils, intracellular neurofibrillary tangles (NFT), as well as
chronic inflammation and widespread synaptic and neuronal
loss, leading to brain atrophy and dysfunction. The deposition
of amyloid plaques is suggested as a defining feature of the
AD brain, as NFT are featured in other neurodegenerative
diseases(2,3) (although plaques have also been reported in cases
of non-AD dementias). Nevertheless, hyper-phosphorylated tau
protein, the major component of NFT, may have a critical role in
the progression of AD, as it acts together with the major protein
component of amyloid plaques, β amyloid (Aβ peptides),
driving neurodegeneration(4,5). The Aβ peptide is generated
from its parent molecule, amyloid precursor protein (APP),
via sequential proteolytic processing by the enzymes
β-APP-cleaving enzyme-1 (BACE1) and γ-secretase(6), to
generate multiple Aβ forms of varying amino acid lengths.
Aβ peptides aggregate readily into oligomers and fibrils, and
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small oligomers of the longer, more easily aggregating
42-amino-acid form (Aβ1-42) are considered to be the most
neurotoxic Aβ species in the AD brain. Amyloid deposition
is thought to occur early in the disease process(7), and the
accumulation of small Aβ aggregates (‘oligomers’) is thought to
have a critical role in early pathogenic events that include tau
hyperphosphorylation and accumulation, oxidative stress and
inflammatory processes that lead to neurodegeneration in the
AD brain(4,8,9).
With no current effective disease-modifying treatments available,
finding pharmacological/non-pharmacological strategies to halt or
slow disease progression is of significant importance. The failure of
potential pharmaceuticals in human clinical trials has highlighted
the need for research into early diagnosis of AD. This is because of
the considerable synaptic loss, neuronal loss and brain shrinkage
already present by the time AD clinical symptoms emerge, with
treatments aimed at slowing the progress of the disease more likely
to be effective before onset of symptoms, preferably at the earliest
pre-clinical stage. The continuing lack of effective pharmaceutical
drugs has also prompted the evaluation of alternative therapeutics,
such as nutraceuticals. Curcumin is one example where, because
of its properties as an anti-inflammatory, antioxidant, Aβ-lowering
agent and Aβ aggregation inhibitor, it shows potential as a
therapeutic for AD. In addition, because of its ability to fluoresce
and bind Aβ, curcumin has potential as an imaging agent for
diagnostics. This review outlines in vitro, in vivo and human
studies that have evaluated the therapeutic potential of curcumin in
AD, and it discusses recent research that has assessed curcumin as
a diagnostic tool through its use in emerging retinal imaging
technologies. All human studies identified in this review met
current National Institute of Health and the Alzheimer’s Association
diagnostic guidelines(10).
Beneficial properties of curcumin – historical perspective
Curcumin is extracted from turmeric, a spice that is derived from
the rhizomes of Curcuma Longa and which belongs to the
Zingiberaceae (ginger) family. Turmeric is a perennial herb,
native to the monsoon forests of south-east Asia, and it is
commonly used in Indian, Asian and Middle Eastern foods. In
addition to being used as a culinary spice, turmeric (Sanskrit
Haridra, meaning that which is yellow) has been a frequently
prescribed herbal medicine. Reputed for its blood-purifying
abilities(11–13), Ayurveda medicine and traditional Persian and
Chinese medicine have prescribed curcumin for centuries for its
body-cleansing properties, as well as for pain associated with
inflammation of the skin and muscles. Curcumin has also been
prescribed for asthma, bronchial hyperreactivity, allergy,
anorexia, coryza, cough, sinusitis and hepatic disease(14).
Only 3–5 % of turmeric comprises the yellow-pigmented
chemically active curcuminoids, being curcumin (diferuloyl-
methane), demethoxycurcumin (DMC) and bisdemethoxy-
curcumin (BDMC)(15). Curcumin, considered the most
therapeutic of the three curcuminoids, was first isolated in 1815
by Vogel and Pelletier(16), although its chemical structure was
not confirmed until almost a century later(17).
The twenty-first century has witnessed renewed interest in
curcumin’s reputed therapeutic effects, which has resulted in
considerable scientific enquiry and review(13,16,18–21). Cell
studies(22–24) report curcumin to possess powerful anti-
inflammatory properties, whereas further research in a variety
of inflammatory conditions demonstrates its potential. For
example, animal and cell culture studies show that curcumin
reduces inflammation in arthritis(25,26); human cell line studies
show that curcumin is effective in the management of irritable
bowel syndrome(27) and in human clinical trials for psoriasis and
other skin disorders(28,29). Anti-proliferative and anti-angiogenic
influences of curcumin have also been demonstrated, and its
therapeutic benefits are shown in human cancer cell and tissue
culture, including prostate(30), breast(31), pancreatic(32) and bowel
cancer(33), as well as head and neck squamous cell carcinoma(34).
Curcumin is also considered a powerful antioxidant, reported to
be several times more potent than vitamin E as a free-radical
scavenger(35). Curcumin’s anti-inflammatory and antioxidant
properties have more recently been investigated with respect to
AD, as it is now well established that oxidative stress(36) and
chronic inflammation are central in the early pathogenic stages of
AD(37). However, in addition to curcumin altering AD development
through anti-inflammatory and antioxidant properties, curcumin’s
ability to bind to Aβ, influence deposition and aggregation, while
possibly also modulating tau processing, has attracted considerable
interest in AD research laboratories(38–41).
Extracellular Aβ plaques and intraneuronal hyper-
phosphorylated tau are recognised as hallmark neuropathological
features of AD(42–44) in addition to oxidative stress and
inflammation, and it is believed that abnormal Aβ metabolism,
resulting in high levels of toxic Aβ oligomers, combined with
oxidative stress and inflammation form an AD pathogenic
cycle of neurodegeneration. While the initiating step of this
neurodegeneration remains to be elucidated, these changes are
thought to begin decades before clinical diagnosis; in fact, the
accumulation of Aβ has been shown in radiological imaging to
start 20 years or more before the first clinical signs of AD(45).
Aβ accumulation is reported to be associated with impaired
synaptic function(46), reduced neurite outgrowth(47), cerebral
atrophy(48,49) and reduced cognitive performance, particularly
when deposited within the temporal region(50). Synaptic/neuronal
loss and NFT load have been shown to correlate positively with
cerebral atrophy and cognitive decline, whereas cerebral Aβ load
also correlates with cognitive decline, although to a lesser extent(7).
However, there is also a large body of evidence suggesting that
small oligomers of Aβ are particularly toxic to neurons, causing
membrane damage, Ca2+ leakage, oxidative damage, disruptions
to insulin signalling pathways and synaptic function, as well as
mitochondrial damage(51–53). As mentioned above, Aβ-induced
changes are believed to occur early in the disease process,
and the findings indicate that interventions that can interrupt the
production of Aβ or Aβ oligomers, or facilitate their removal
from the central nervous system, are highly desirable. Modelled
projections suggest that delaying the onset of dementia by even
1 year may reduce the worldwide burden of cases in people
over 60 years by as much as approximately 10%(54), whereas the
introduction of an intervention that delays the onset of dementia by
5 years could reduce the incidence by almost half(55,56). Therefore,
early pre-clinical prevention therapy, which could influence the
accumulation or clearance of cerebral Aβ and tau pathology, and/or
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reduce oxidative stress and chronic inflammation, thus slowing
or reversing these pathological changes, would be highly significant
for the reduction of AD prevalence.
Potentially neuroprotective properties of curcumin: animal
studies and in vitro anti-β amyloid activity of curcumin
prevents β amyloid aggregation
The Aβ peptide aggregates readily, first into small aggregates of Aβ
known as Aβ oligomers and then these oligomers aggregate
further to form fibrils, larger fibrils and ultimately plaques of Aβ.
Although plaques and large fibrils are the easiest to detect
immunohistochemically, these are considered to be relatively
inert: as mentioned above, there is now considerable evidence
that small Aβ oligomers are the main neurotoxic species(57).
Therefore, it is interesting that substantial data from in vitro
studies indicate that curcumin can bind to Aβ and influence its
aggregation. For example, curcumin has been shown to inhibit
fibril formation and extension, as well as to destabilise pre-formed
fibrils in a dose-dependent manner, effective at concentrations
about 0·1–1·0 µM(58). Later studies have similarly shown that
curcumin can inhibit the formation of small Aβ aggregates
(Aβ oligomers) in a dose-dependent manner(59,60).
Studies have investigated how curcumin influences Aβ
aggregation, and different theories have emerged – for example,
one theory involves curcumin binding to metal ions. Biometals
such as Cu (Cu(II)) and Zn (Zn(II)) are found in abundance in the
brain, particularly at synapses. Dysregulation of metal homeostasis
can lead to the binding of these particular metal ions to Aβ,
and many studies have shown that this binding accelerates Aβ
aggregation. In fact, elevated levels of certain metal ions have been
associated with AD(61), and considerable research has been
undertaken to understand the normal roles of these ions in
the brain, as well as the roles the ions may have in disease
pathogenesis, particularly the roles of Cu(II) and Zn(II) on Aβ
aggregation(62). Some recent studies have suggested that curcumin
complexes with Cu(II) and/or Zn(II) and that this inhibits
the transition from less structured oligomer to β-sheet-rich Aβ
protofibrils, which in turn act as seeding factors for further Aβ
fibrillisation(63). Recent studies looking at the effect of curcumin
and curcumin derivatives on metal-induced Aβ aggregation have
shown that Gd-linked curcumin (Gd-Cur, a potential Aβ imaging
agent), compared with curcumin and Cur-S, a water-soluble form
of curcumin, could modulate Cu-induced Aβ aggregation to
a greater extent(64), supporting the concept of therapeutic and
diagnostic uses for the Gd-Cur compounds.
Other theories do not involve metal ions; instead, they suggest
that curcumin’s ability to bind Aβ and inhibit its aggregation is
because of curcumin’s three structural features: a hydroxyl
substitution on the aromatic end group, a rigid linker region
between 8 and 16 Å in length and a second terminal phenyl
group(59). More recent studies using atomic force microscopy have
found that curcumin (and another small-molecule inhibitor
resveratrol) binds to the N terminus (residues 5–20) of Aβ1-42
monomers and prevents oligomers of 1–2 nm in size from
becoming larger 3–5 nm oligomers(65). Yet another recent study
has used NMR spectroscopy to investigate the structural
modifications of Aβ1-42 aggregates induced by curcumin, and
found that curcumin induces major structural changes in the
Asp-23–Lys-28 salt bridge region and near the Aβ1-42
C terminus(66). The study also used electron microscopy to show
that the Aβ1-42 fibrils are disrupted by curcumin. Interestingly, in a
Drosophila AD model, curcumin-fed flies showed accelerated
conversion of pre-fibrillar to fibrillar Aβ, thereby reducing the
neurotoxicity of pre-fibrillar Aβ(67). Overall, curcumin effects are
not limited to modulation of Aβ aggregation, and further studies
are needed to determine which effect(s) are the most relevant in
promoting brain health in pathological cognitive decline.
Curcumin influences β amyloid production
In vitro studies have shown that Aβ production is influenced by
curcumin, as curcumin has been found to inhibit the production of
Aβ peptides by altering APP trafficking through the secretory
pathway(24). Zhang et al. treated mouse primary cortical neurons
with different concentrations of curcumin (1–20 μM) for 24 h and
found that both Aβ1-40 and Aβ1-42 levels significantly decreased
compared with controls. It was suggested that curcumin could
stabilise an immature form of APP and reduce the amount
reaching the cell surface, thus being available for endocytosis –
a process necessary for Aβ production. In an APP-transfected
human embryonic kidney cell culture model (SwAPP HEK293),
BDMC was shown to reduce BACE1messenger RNA (mRNA) and
protein levels, whereas DMC only affected BACE1 mRNA
expression(68). Furthermore, in other studies using a neuronal cell
line (pheochromocytoma cells – the PC12 cell line) 3–30 µM cur-
cumin suppressed Aβ-induced BACE1 up-regulation(69,70). Most
recently, in studies of an AD Drosophila model, it was found that
the curcumin component BDMC was the most effective at res-
cuing the flies from the morphological and behavioural defects
caused by the overexpression of APP and BACE1(71), possibly via
inhibition of the BACE1 enzyme. Recognising curcumin’s ability to
reduce Aβ production, by reducing BACE1 mRNA and its
corresponding protein(72), curcumin has been used as a potent
positive control in the analysis of other compounds/drugs that
target not only BACE1 but also metal chelation, Aβ aggregation
and oxidation(73). In support of curcumin’s metal chelation
properties, curcumin was shown to prevent the up-regulation of
APP and BACE1 induced by supraphysiological levels of the metal
ions Cu(II) and Mn(74).
Curcumin can inhibit β amyloid-induced toxicity
Previous studies support the notion that curcumin can reduce
Aβ-induced toxicity. A study by Park et al.(75) used PC12 cell
cultures pre-treated with 10 μg/ml curcumin before Aβ exposure.
Compared with controls, pre-treated cells had a significant
reduction in oxidative stress, as well as lower Ca influx, resulting
in protection against DNA damage and cell death. Curcumin
(1–30 μM) has also been shown to attenuate the production of
Aβ-induced radical O2 species in neuronal cell cultures, and 20 μM
curcumin has been shown to prevent structural changes in Aβ
towards β-sheet-rich secondary structures(69). Furthermore, the
protection curcumin provided to PC12 cells and to human
umbilical vein endothelial cells against Aβ1-42-induced injury
was attributed by Kim et al.(76) to antioxidant mechanisms of
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curcuminoids. More recently, in vitro studies of microglia have
shown that curcumin can dampen inflammatory pathways
that promote neurodegeneration(77). In this study, curcumin
dose-dependently improved viability against Aβ-42-induced
inflammation, as it abolishes Aβ-42-induced IL-1β, IL-6 and
TNF-α production. Curcumin was also shown to reduce ERK1/2
and p38 phosphorylation, which was then shown to reduce
cytokine production by the microglia(77).
Curcumin’s neuroprotective properties may also be attributed to
its role in cell signalling. Cell signalling by the Wnt pathways,
via the transcription co-activator β-catenin, controls embryonic
development, cellular proliferation and neurogenesis. Disruptions
to this pathway have been shown to have a significant role in the
pathogenesis of diverse diseases such as cancer, metabolic
diseases, osteoporosis, epilepsy, as well as AD. In studies of
APP-transfected neuroblastoma cells, curcumin was found to
activate the Wnt/β-catenin signalling pathway by inhibiting the
activity of glycogen synthase kinase 3β (GSK-3β)(78). GSK-3β is a
negative regulator of Wnt, and thus lowering its activity will activate
Wnt. However, just as importantly, constitutively active GSK-3β
contributes to aberrant tau phosphorylation and NFT formation,
which are hallmark pathological changes in AD(79), and thus
curcumin-induced inhibition of GSK-3β may also reduce NFT
formation. However, the benefits of curcumin in attenuating tau
phosphorylation and accumulation have yet to be investigated
thoroughly. Interestingly, Aβ oligomers have also been shown to
inactivate Wnt in hippocampal slices, by inducing the Wnt
antagonist Dickkopf-1(80). These studies collectively suggest that
curcumin can influence GSK-3β and Wnt/β-catenin signalling,
which are both key factors in AD pathogenesis(81). Furthermore,
it has been shown recently that activation of the Wnt/β-catenin
signalling pathway inhibits the transcription of BACE1 by binding
of T-cell factor-4 to the BACE1 promoter gene, thereby reducing
the generation of Aβ(82). Other recent studies using molecular
modelling software programs have identified curcumin and
rosmarinic acid as promising ligands that mimic the inhibitory
action of peptidyl inhibitors of caspase-3(83). The relationships
between AD-related proteins and pathways discussed above
provide further indication of curcumin’s therapeutic potential for
the prevention of AD.
Curcumin and the clearance of β amyloid
One anti-AD therapeutic approach involves enhancing the
clearance of Aβ from the brain. Several mechanisms have been
proposed to assist normal clearance of Aβ from the brain, such
as enhancing receptor- or apo-mediated transport across the
blood–brain barrier (BBB), efflux of Aβ from the brain being the
basis of the peripheral sink hypothesis, targeted immune
responses to Aβ, dissolution of amyloid fibrils and microglial
activation resulting in phagocytosis of amyloid plaques, as
reviewed by Bates et al.(84). The significance of the innate immune
system in Aβ clearance remains pertinent to intervention and
treatment modalities. Although previous attempts to use vaccines
to augment the immune response were halted because of the
incidence of sterile encephalitis(85), interest in this area remains
strong. Macrophage activity and phagocytosis of Aβ has been
reported to be deficient in AD, suggesting a contributory factor to
Aβ accumulation(86). Furthermore, a later study that pre-treated the
AD macrophages with curcuminoids resulted in increased Aβ
uptake in 50% of the macrophages(87).
Curcumin’s ability to reduce oxidative damage and amyloid
pathology in AD transgenic mice, demonstrated by Garcia-Alloza
et al.(40), also suggests that curcumin can influence amyloid-
induced cytopathology, or macrophage processing of amyloid.
Garcia-Alloza et al. used multi-photon and in vivo imaging to
reveal a marked amyloid clearance effect, with 30% plaque
size reduction and slowed plaque development, in animals
receiving curcumin for 7 d via intravenous tail injections.
Fiala et al.(86) examined curcumin’s effect on enhancing
phagocytosis of Aβ at a molecular level, and found that curcumin
restored the normal Aβ-induced up-regulation of the transcription
of β-1,4-mannosyl-glycoprotein 4β-N-acetylglucosaminyltransferase
(MGAT3), an enzyme thought to be involved in phagocytosis.
Other proteins such as toll-like receptors were also up-regulated.
These results indicate that curcumin may correct immune
defects in AD patients, suggesting a novel approach to AD
immunotherapy(88). In more recent studies by the same group,
it was found that 1α,25(OH)2-vitamin D3 (1,25D3) could restore
the defective Aβ phagocytosis in AD macrophages, and that
a nuclear vitamin D receptor antagonist could block this
phagocytosis. All phagocytes seemed to respond to 1,25D3,
yet only a subset responded to curcuminoids by up-regulating
MGAT3. Nevertheless, in those who did respond, further
studies demonstrated that the 1,25D3 bound to a pocket of
the vitamin D3 receptor that influences genomic events, and
curcuminoids bound to a non-genomic pocket(89,90), produced an
additive effect.
Curcumin effects on lipid metabolism
Early research(91–93) reported that curcumin had cholesterol-
lowering ability, supported by Peschel et al.(94) who reported
that curcumin has a hypocholesterolaemic effect, based on its
effect on hepatic gene expression. Feng et al.(95) also found
curcumin to lower cholesterol levels through suppression of
Niemann Pick C1-like 1 protein, which is responsible for
the uptake of cholesterol through vesicular endocytosis
within the intestine. Another potential mechanism for the
hypocholesterolaemic effect of curcumin was revealed in
studies of rats fed a high-fat diet, in which curcumin was
found to decrease significantly the serum levels of TAG, total
cholesterol and LDL-cholesterol, when compared with a control
group: curcumin was found to up-regulate mRNA levels of
cholesterol 7α-hydroxylase (CYP7A1), a rate-limiting enzyme in
the biosynthesis of bile acid from cholesterol(96). More recently,
treatment of similar high-fat diet-fed rats with curcumin
combined with piperine was found to produce similar changes
to the serum lipid profiles of the rats and increased HDL levels,
resulting in significant up-regulation of the activities and gene
expression of apo A-I, lecithin–cholesterol acyltransferase,
CYP7A1 and the LDL receptor(97). As hypercholesterolaemia
continues to be considered a likely contributor to AD risk(98,99),
the use of curcumin if proven to lower cholesterol could
represent another approach, adding to the armoury for AD
risk reduction.
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Curcumin and telomerase
Xiao et al.(100), investigating the role of telomerase (a ribo-
nuclear protein complex that synthesises and elongates telo-
meric DNA) in the neuroprotective efficacy of curcumin, found
curcumin to be protective against Aβ-induced oxidative stress
and cell toxicity. This neuroprotection was lost when telomer-
ase was inhibited by telomerase RT small interfering RNA,
indicating that the neuroprotection provided by curcumin was
dependent on the presence of telomerase.
Focusing on findings in animal studies
Several in vivo studies have found that Aβ deposition and
plaque burden in AD-model transgenic mice is decreased fol-
lowing treatment with curcumin(40,60,101,102). Curcumin has also
been found to inhibit Aβ-induced tau phosphorylation(103), to
reduce microglial activation, indicating a reduction in inflam-
mation(102,104), and reduced oxidative damage(104). Other stu-
dies of transgenic mouse models of AD have shown that
curcumin can reduce genomic instability events(105).
In the study by Lim et al.(101), AD-model Tg2576 mice aged
10 months old were fed a curcumin diet (160 parts per million
(ppm)) for 6 months. The results showed that the curcumin diet
significantly lowered the levels of oxidised proteins, the
inflammatory cytokine, IL-1β, the astrocyte marker glial fibrillary
acidic protein (GFAP), soluble and insoluble Aβ and also plaque
burden. The study found that the reduction in GFAP was
localised, such that increased activity was shown in areas
around plaques, demonstrating a stimulatory effect of curcumin
on the phagocytosis of plaques by microglia. Frautschy
et al.(104), using Sprague–Dawley rats infused with Aβ40 and
Aβ42 to induce neurodegeneration and Aβ deposits, found
that dietary curcumin (2000 ppm (5·43 μmol/g)) suppressed
Aβ-induced oxidative damage and memory impairment, and
increased microglial labelling within areas adjacent to Aβ
deposits. They also found that curcumin reversed changes in
synaptophysin and post-synaptic density 95 (PSD-95) levels,
associated with brain plasticity, as well as improved rat per-
formance in length and latency within the water maze test(104).
In similar studies of aged Tg2576 AD-model mice by Yang
et al.(60), it was demonstrated that curcumin injected periphe-
rally (via the carotid artery) can cross the BBB and bind to
amyloid plaques and inhibit the formation of Aβ oligomers and
fibrils(60). Later, Begum et al.(15) showed similar results and
suggested that the dienone bridge present in the chemical
structure of curcumin is necessary for this reduction in plaque
deposition and the lower protein oxidation observed in the
curcumin-treated Tg2576 mice.
More recently, Belviranli et al.(106) showed that aged female
rats supplemented with curcumin for 12 d demonstrated
improved spatial memory (Morris water maze test), and their
brains exhibited reduced oxidative damage. In other studies
using an Aβ-infused male Sprague–Dawley rat model of AD, the
effects of combined curcuminoids, as well as the individual
curcumin constituents, were examined in relation to genes
related to synaptic plasticity. The genes that were investigated
included actin, Ca/calmodulin-dependent protein kinase
type IV, PSD-95 and synaptophysin, and significant effects were
noted; for example, a significant increase in synaptophysin
expression was found following treatment of the hippocampus
with curcuminoids, and both DMC and curcumin were found to
increase PSD-95 expression several-fold(107), demonstrating
results similar to the earlier rat study carried out by Frautschy
et al.(104).
Curcumin and neurogenesis
Curcumin has also been found to stimulate proliferation of
embryonic neural progenitor cells and neurogenesis in the adult
hippocampus, demonstrating other potentially beneficial effects on
neuroplasticity(108). In this study, intraperitoneally administered
curcumin activated extracellular signal-regulated kinases (ERK) and
p38 kinases, which function in cellular signal transduction pathways
that are known to be involved in the regulation of neuronal
plasticity and stress responses. More recently, a hybrid compound
of curcumin and melatonin (5-(4-hydroxy-phenyl)-3-oxo-pentanoic
acid (2-(5-methoxy-1H-indol-3-yl)-ethyl)-amide), known as Z-CM-
I-1, developed with the aim of improving neuroprotective proper-
ties and BBB permeability, was found to reduce Aβ accumulation
in the hippocampus and cortex of APP/PS1 transgenic mice,
and to increase the expression of the synaptic markers
synaptophysin and PSD-95, following oral administration at a dose
of 50mg/kg for 3 months(109), encouraging further development
of this hybrid compound. APP/PS1 mice were also used in
another recent study, which tested the effect of 6 months’ dietary
supplementation with the curcumin derivative 1,7-bis(4'-hydroxy-
3'-trifluoromethoxyphenyl)-4-methoxycarbonylethyl-1,6-heptadiene-
3,5-dione (FMeC1). It was found that FMeC1 supplementation
resulted in less Aβ deposits, glial cell activity and cognitive
deficits, when compared with untreated, curcumin-treated
or FMeC2-treated mice, suggesting that FMeC1 has potential
in the treatment of AD(110). In rat studies, genetic transcriptional
responses along with enhanced hippocampal neurogenesis
was seen, following 12 weeks of administration of a curcumin-
containing diet, as compared with 6 weeks of this diet, or a
control diet(111), providing further evidence that curcumin
may be beneficial through the promotion of neuronal cell
growth.
Curcumin and the blood–brain barrier
Studies of rat and mouse models of ischaemic damage found
that curcumin could protect the BBB, most likely because of
anti-inflammatory and antioxidant effects(112,113), and later stu-
dies of cerebral ischaemia in rats found that a single intravenous
injection of curcumin could reduce infarct volume and neuro-
logical deficit, possibly because of inhibition of inducible nitric
oxide synthase(114). More recent studies suggest that curcumin
up-regulates heme oxygenase-1 expression to reduce damage
and permeability of the BBB(115). Encouragingly, an in vivo rat
study, using nanoparticulation of curcumin, was able to
demonstrate increased organ, as well as the brain, perfusion by
curcumin, by prolonging retention time in the hippocampus by
83 % and in the cerebral cortex by 96 %(116). More recently,
another group produced a highly stable nanocurcumin
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formulation (particule size <80 nm) for use within an in vitro
and in an AD transgenic mouse model. The study showed
higher concentrations of the nanoformulation in plasma and
within the brain compared with non-capuslated curcumin or
placebo, while demonstrating significant improvements in
working and cued memory function(117).
Curcumin analogues with similar biological activity to curcumin,
yet with improved pharmacokinetic characteristics, including
increased bioavailability and water solubility, are continuing to
be developed(118,119), while new synthetic products are also
emerging(119). Nanotechnology is particularly promising, whereby
nanoencapsulation may be able to achieve a synergistic drug
delivery system(120). Encouraging results have already been
reported in a study examining curcumin for use in breast cancer
chemoprevention, which used injectable polymeric micro
particles in mice, achieving both sustained blood curcumin levels
for almost a month while maximising its BBB penetration, as well
as inhibiting tumour vasculature(121). Other studies exploring
nanoparticle technology(122,123) have been equally promising. For
example, following the intravenous administration of liposomal
curcumin, polymeric nanocurcumin and poly-lactic-co-glycolic
acid co-polymer-curcumin in rats, all of these compounds were
found to cross the BBB(122), whereas in another study
nanoparticles containing curcumin were shown to increase oral
bioavailability 9-fold(123). Further evidence of BBB penetration has
been obtained in animal models using labelled curcumin
derivatives(119).
Curcumin and acetylcholinesterase
In addition to the effects above, curcumin has also been shown
to influence acetylcholinesterase activities(124), following the
same pathway as the commonly prescribed pharmaceuticals,
acetylcholinesterase inhibitors, which are considered first-
line management in AD(18,125). The administration of
acetylcholinesterase inhibitors has been found in certain
circumstances to slow the progression of AD symptoms or even
reduce AD symptoms for a 12-month period, by inhibiting the
breakdown of acetylcholine, a major neurotransmitter, depleted
in the AD brain. Using in vitro and ex vivo models of
acetylcholinesterase activity, Ahmed et al.(107) investigated
whether curcumin had an influence on acetylcholinesterase
mechanisms, and recorded dose-dependent inhibitory effects in
the frontal cortex and in the hippocampal tissue; curcuminoids
also demonstrated significant attenuation of scopolamine-induced
amnesia. Furthermore, Ahmed et al.(107) examined the influence
of curcumin on spatial memory in amyloid-infused AD rat models,
reporting increased PSD-95 and synaptophysin expression in the
hippocampus and a memory-enhancing effect. In studies of
streptozotocin-induced diabetic rats, curcumin has been shown to
prevent cholinergic-mediated cortical dysfunctions, which are
induced by diabetes(126), and in mice treated with okadaic acid to
induce memory impairment orally administered curcumin
has been found to improve cholinergic function and reduce
inflammation, among other beneficial effects(127). Furthermore,
curcumin has been shown to reverse alcohol-induced cognitive
deficits in the adult rat brain, partly by preventing the alcohol-
induced activation of acetylcholinesterase; curcumin also reduces
signs of neuroinflammation in these rats(128). Another rat study
indicated that curcumin may inhibit acetylcholinesterase activity in
As- and Al-induced toxicity models(129).
Despite all these animal studies, the influence of curcumin on
acetylcholinesterase has not yet been investigated in human
clinical studies. Furthermore, mechanisms underlying many
of the effects described above are still being characterised.
However, there is now evidence of curcumin derivatives
influencing proteasomal function and Aβ degradation, as
described below.
Curcumin, proteasome function and β amyloid degradation
Proteasomal activity and its role in the degradation of most
oxidised proteins is linked with the processes of cell ageing; it is
also believed that age-related decreases in proteasome activity
weakens a cell’s capacity to remove oxidatively modified
proteins and therefore encourages the development of
diseases(130). Curcumin has been demonstrated to have a
stimulatory effect on proteasomal activity, causing a 46 %
increase in activity at doses of 1 µM in vitro, whereas higher
doses, not likely to be achieved in vivo, led to decreased
activity(131). More recent studies have shown that a synthetic
derivative of curcumin, CNB-001, can stimulate Aβ degradation
through both proteasomes and lysosomes, and the
experimental inhibition of the proteasome pathway redirects
clearance through lysosomes. Other recent CNB-001 studies
have provided a link between the findings of several other
AD-related biochemical changes. These include the findings
that levels of the enzyme 5-lipoxygenase (5-LOX) are elevated
in AD(132) and that disruption of this enzyme and some
phospholipases can reduce AD pathology(133,134); as well as
that chronic stress can cause cell signalling/over-activation of
regulatory kinases, which in turn leads to the phosphorylation
of the eukaryotic initiation factor-2α (eIF2α) and disrupts
the translation activation of several mRNA, and detected in
neurodegenerative diseases including AD(135). The CNB-001
studies found that CNB-001 could inhibit 5-LOX, which induces
the eIF2α phosphorylation. Furthermore, when fed to AD
transgenic mice, CNB-001 was found to increase
eIF2α phosphorylation (as well as heat shock protein 90 and
activating transcription factor 4 levels), improve Aβ clearance
and therefore limit the accumulation of soluble Aβ and
ubiquitinated aggregated proteins. CNB-001 has also been
found to maintain the expression of synapse-associated
proteins and to improve memory in the mice(136). These
studies indicate that the curcuminoid derivative’s inhibition of
5-LOX has potential as a therapeutic approach.
Overall, cell culture and animal studies have indicated
that curcumin has considerable potential as an inhibitor of
Aβ aggregation, as an antioxidant, an anti-inflammatory and
as an inhibitor of BACE1. Curcumin, among its modalities
of action, has also shown promise in facilitating Aβ clearance/
degradation, inhibiting tau phosphorylation, promoting
neurogenesis and modulating synaptic plasticity (Fig. 1).
Despite these benefits, there is a paucity of population-
based studies examining the protective role of curcumin
on cognition.
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Effects of curcumin on human cognition
Only a handful of clinical studies have been carried out to
evaluate the cognitive enhancing potential of curcumin in AD
patients(137,138); however, these have not been particularly
successful. Reasons could be because of the low bioavailability of
curcumin(15), thereby markedly reducing its potential to reach the
brain at sufficient concentrations to provide benefits. Alternatively,
the subjects may have been treated at a stage of pathology that is
too advanced for curcumin to provide benefits. Nevertheless, there
are epidemiological data that support the concept that
curcumin can reduce the risk of AD. For example, India, with
an estimated average daily consumption of curcumin being
80–200mg(21,139), has been reported to have a lower incidence and
prevalence of AD(140–142), although under-reporting and clinician
access may be a contributor. Nevertheless, a study of 1010
cognitively intact Asian participants aged 60–93 years has found
that those who consumed curry (which contains turmeric) more
often, compared with those who ate curry very rarely or never,
performed better on the Mini Mental State Examination
(MMSE)(143). These observations, among others, support the
concept that turmeric, and in particular its curcumin particle,
may possess valuable neuroprotective or cognitive-enhancing
properties. However, as mentioned above, clinical trials
examining the efficacy of curcumin in patients with cognitive
decline have been disappointing; however, more recently, with
studies using improved formulations and more appropriate
cohorts, encouraging signs are emerging(144). Table 1 represents a
list of ongoing/completed clinical trials that have used curcumin for
the diagnosis, prevention or treatment of AD. These trials are
discussed further below.
Baum et al.(137) randomised AD patients (n 34) to receive 1 g
(plus 3 g placebo), 4 g (plus 3 g placebo) or 0 g of oral curcumin
(plus 4 g of placebo), once daily. Participants were given the choice
of formulation, being either powder or capsule. The intervention
group did not demonstrate significant differences in MMSE scores
or plasma Aβ-40 levels between 0 and 6 months; however, it was
suggested that the outcome measures were not sensitive or specific
enough to demonstrate effects(137). Ringman et al.(145) conducted a
24-week, randomised, double-blind, placebo-controlled study
evaluating the efficacy of two dosages of curcumin (2 and 4 g/d) in
patients with mild-to-moderate AD, with an open-label extension
for 48 weeks. This was the first study to include measurement of
cerebrospinal fluid (CSF) biomarkers. The preliminary results
showed no significant differences in cognitive function, in plasma
or CSF Aβ-40/Aβ-42 or tau, between placebo and intervention
groups; however, bioavailability was again reported as a limitation,
although the dosing was well tolerated.
The above studies included AD-diagnosed participants, in whom
significant neurodegeneration and AD pathology already exists.
Given that the pathological changes begin two decades or more
before the first recognisable symptoms(45), targeting healthy older
cohorts or those in the pre-clinical or prodromal AD phase would
more likely provide benefits through slowing the pathogenic
mechanisms. Considerable synaptic and neuronal loss has already
occurred by the time symptoms appear, and the antioxidant,
anti-inflammatory and Aβ-lowering and anti-Aβ aggregation
properties of curcumin are most likely to be of benefit in the early
stages, for the prevention of AD pathogenesis. However, curcumin
treatment of AD patients may still provide many benefits, and it
warrants further clinical evaluation.
More recent studies have evaluated curcumin’s effects under
normal physiological conditions. In a placebo-controlled study
targeting healthy middle-aged subjects (n 38, 40–60 years),
80 mg of curcumin (400mg of Longvida-optimised curcumin)
was given orally for 4 weeks to assess the health-promoting
effects of curcumin(146). This study, because of the diverse
health claims of curcumin, investigated several blood and saliva
biomarkers, to examine the effect of curcumin on markers
associated with lipids, inflammation, liver function, immunity
and stress, as well as Aβ levels. Cognitive measures were not
included in their study design. Statistically significant results
were shown for a number of these markers including increased





























Fig. 1. Curcumin: reported mechanisms of action. BACE1, β-APP-cleaving enzyme-1; Aβ, β amyloid; APP, amyloid precursor protein.
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Table 1. Studies using curcumin in Alzheimer’s disease (AD): diagnosis, prevention and treatment
Study Agent Cohort Dose Duration End points and brief summary of results
Baum et al.(137) (NCT00164749) Curcumin and
ginkgo
Probable AD; 50 years+; n 30 1, 4 g daily 6 months Safety and effects, biochemical and cognitive
measures
No differences detected between treatment groups in
Aβ levels or MMSE scores
Ringman et al.(145) (ACT00099710) Curcumin C3
complex®
Mild/moderate AD; age 49 years+;
n 30
2, 4 g daily 24 weeks plus
24 open label
Side effects, blood biomarkers and cognition
No differences detected between treatment groups in
clinical or biomarker efficacy measures; results also
indicated low bioavailability
Hishikawa et al.(150) Turmeric capsules Severe AD; n 3 100mg curcumin
daily
12 months, tested after
12 weeks
MMSE and NPIQ; score on NPIQ decreased
significantly, MMSE increased in 1/3
Poncha (NCT01001637) Longvida™ Moderate – severe AD; 50–80 years;
n 160
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plasma alanine aminotransferase and TAG, but not total cho-
lesterol. In addition, curcumin was found to lower plasma Aβ
levels. Another interesting finding was that salivary amylase was
also significantly lowered, which is an enzyme associated with
adrenergic activity during stress(147).
A number of studies of curcumin supplementation in healthy
older subjects are still in progress. However, one such study has
been completed: a randomised, double-blind placebo-
controlled study (n 60, 60–85 years) using the same 80 mg/d
curcumin formulation as used by DiSilvestro et al.(146) (400 mg
of Longvida-optimised curcumin). The authors reported acute
(1 h post dose) and chronic (1-month duration) effects of
curcumin intake on cognition, mood and blood biomarkers(144).
Benefits on attention and working memory were reported
following the acute administration of curcumin, whereas
at the 1-month time point, working memory and mood
improved. Alertness and contentedness also improved after
acute-on-chronic treatment.
Although the results above are encouraging, alternate
mechanisms, including modulation of the stress response, may
have played a part. Amylase, shown to be lowered in an earlier
study using curcumin(146), is a recognised biomarker of
β-adrenergic stimulation(147–149), and improved attention, working
memory and contentedness may be linked to this mode of action.
No alterations in blood levels of Aβ-40 or Aβ-42 levels were
detected, although these are not thought to be reliable biomarkers
on their own. Differences in cognitive performance, as
demonstrated in serial 7-s and delayed recall, were not
significant(144). Nevertheless, curcumin did enhance the lipid
profile by lowering LDL, and in contrast to the results found by
DiSilvestro et al.(146), Cox et al.(144) also recorded a reduction in
plasma total cholesterol. Long-term lipid changes such as these
may have some effect on AD risk: as mentioned earlier, chronic
conditions linked to abnormal lipid profiles such as obesity and
diabetes are linked with a higher risk of AD. Interestingly, a
case study reported by Hishikawa et al.(150) found that three
severe-stage AD patients treated with 100mg/d oral curcumin
for 12 weeks (in addition to their already prescribed
acetylcholinesterase inhibitor, donepezil) showed a reduction in
agitation, anxiety and irritability; one patient also showed
improvement in MMSE score. This may suggest a role for
curcumin as a concurrent intervention, and it supports the concept
that curcumin may provide benefits, even in advanced stages of
AD; however, further research would be required to support these
suggestions.
As mentioned earlier, several other clinical studies are still
underway, or results have not yet been published; thus, with so
few clinical studies having been completed, it is not possible to
make any conclusions concerning the clinical significance of
curcumin in enhancing cognition.
Epigenetics, Alzheimer’s disease and curcumin
Epigenetic alterations have been reported to occur in AD(151–154).
As epigenetic alterations are dynamic, these alterations have been
proposed as a target area for AD prevention. Epigenetic alterations
include changes in DNA methylation, histone modifications or
changes in miRNA expression. Studies including some clinical
studies of other conditions have shown that curcumin has the
potential to induce epigenetic changes(155,156). For example,
epigenetic effects of curcumin have been shown in patients with
breast cancer and advanced pancreatic cancer, and also in people
at risk of stroke, by providing vascular protection(157). Curcumin
has been shown to inhibit DNA methyltransferase, histone
acetyltransferase and histone deacetylase, and to modulate miRNA,
for example down-regulating microRNA-134 and microRNA-124 in
cultured hippocampal slices, which are associated with an increase
in the brain-derived neurotropic factor (BDNF)(158). BDNF has
been shown to increase hippocampal neuronal survival and to
enhance synaptic plasticity. Furthermore, variants of the BDNF
gene have been linked to several mental disorders such as major
depressive disorder (MDD) and schizophrenia, and low levels of
BDNF protein are thought to contribute to the pathology of MDD.
Interestingly, antidepressants have also been found to increase
blood levels of BDNF(159). Depression is a major risk factor for AD,
and thus this BDNF-modifying property of curcumin is of
significant interest. Other recent studies have also found that
curcumin can have a significant effect on depression(160),
supported to some extent by the studies described above by Cox
et al.(144)
Many other studies have discovered the beneficial epigenetic
effects of curcumin in relation to various cancers and rheumatoid
arthritis, and now similar benefits are being discovered that may
have an impact on the risk and severity of AD(161). For example,
DNA methylation in neurodegenerative diseases (and many other
conditions such as CVD and stroke) has been linked to high
homocysteine levels, which occur with ageing and with vitamin B12
or folate deficiencies(162,163). Chronically high homocysteine levels
lead to an abnormally high DNA methylation(164), which requires
DNA methyltransferase, and as mentioned above curcumin inhibits
DNA methyltransferase. However, rat studies of homocysteine
effects suggest that curcumin may be neuroprotective, and may
improve learning and memory deficits, by reducing lipid perox-
idation and high malondialdehyde levels, both of which are
induced by high homocysteine levels(165). The relative significance
of these potential benefits of curcumin dietary supplementation are
clearly still not known, and thus further clinical studies are required
to evaluate the neuroprotective role of curcumin induced by
epigenetic regulation for the prevention of cognitive decline.
Curcumin safety profile, tolerability, bioavailability and
mode of administration
As curcumin is a component of the spice turmeric, it is not
surprising that curcumin has been reported to be a very safe
nutraceutical with a low side-effect profile. However, it should be
noted that while curcumin has been reported to be safe and well
tolerated at doses of upto 8 g/d(166), studies have not gone beyond
3 months, and thus the long-term effects of high doses of curcumin
are not known. In addition, with enhanced bioavailability and
absorption now possible with new formulations, the risk of
increased toxicity is higher, particularly for populations taking
medications metabolised by the liver or for those with existing
liver impairment(137). Nevertheless, although curcumin may not
have been tested widely for the purposes of reducing
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neurodegeneration, it has been clinically tested in patients with
various conditions and pro-inflammatory diseases including
cancer, CVD, arthritis, Crohn’s disease, ulcerative colitis, irritable
bowel disease, tropical pancreatitis, peptic ulcer, psoriasis,
atherosclerosis, diabetes, diabetic nephropathy and renal
conditions, among others, and has resulted in minimal side effects
and many health benefits. Curcumin has also provided protection
against hepatic conditions, chronic arsenic exposure and alcohol
intoxication(167).
Curcumin’s pleiotropic effects explain its wide variety of
applications; for example, it has been tested for the purpose of
stent coating, as curcumin has advantageous anti-coagulant
properties(168). In addition, it can inhibit the generation of blood
clotting factors Xa and thrombin via the extrinsic and intrinsic
pathways(169). These properties do indicate that one should be
cautious when prescribing curcumin in combination with other
blood-thinning preparations. Although the safety of curcumin has
been demonstrated(137,145), in humans, oral ingestion of existing
formulations has presented challenges concerning absorption and
bioavailability(145,170). The literature reports that oral curcumin has
efficient first-pass metabolism and some degree of intestinal
metabolism, including glucuronidation and sulphation (although
this occurs mostly in the liver); however, it is excreted largely
unconjugated via the intestine. Curcumin is also unstable at neutral
and alkaline pH. There appears to be minimal distribution of
curcumin to the liver or other tissues beyond the gastrointestinal
tract(171). For example, in rat studies, an oral dose of 500mg/kg
resulted in a peak plasma concentration of only 1·8 ng/ml(172),
with the major metabolites being curcumin sulphate and curcumin
glucuronide, whereas a clinical study found that oral doses of 4, 6
and 8 g of curcumin daily for 3 months yielded serum curcumin
concentrations of only 0·51 (SD 0·11), 0·63 (SD 0·06) and 1·77
(SD 1·87) μM, respectively, with peak levels at 1–2 h post
dosing(166). Unmodified curcumin is reported to be retained in the
blood for 2–5 h in humans, whereas retention of a modified
form of curcumin – Biocurcumax-95 (BCM-95) – is reported as
exceeding 8 h(173). In order for the curcumin to elicit a greater
nutraceutical benefit, it is critical that more of it is able to enter the
bloodstream, it must have a longer half-life and also cross the BBB
to be of significant benefit in AD.
To date, most human curcumin studies have used oral
formulations. Absorption and bioavailability have continued to
be a hindrance, not aided by the variation of formulations
available. However, as technology has advanced and new
delivery approaches have emerged, the use of adjuvant therapies,
isomerisation, liposomes, micelles, phospholipids and nano-
technology also increase. One of the potential therapeutic results of
increasing blood levels of curcumin in humans can hopefully be
anticipated from AD transgenic mouse studies, in which the
intravenous administration of curcumin (7·7mg/kg per d) for 7 d
resulted in significant clearance of cerebral Aβ load(40). Alternate
routes of delivering curcumin are already being used for
other disorders, such as the use of topical eye drops,
recommended for the treatment of a variety of ophthalmic
disorders(174), and transdermal application using encapsulated
curcumin as a nanoemulsion, for the treatment of arthritis(175).
Recently, the curcumin derivative FMeC1, originally produced as
an MRI probe, has been produced in aerosol form for inhalation.
A study in 5XFAD transgenic mice suggested improved
distribution in the brain, and immunohistochemical studies
demonstrated that FMeC1 absorbed following aerosol delivery did
bind to amyloid plaques in the mouse brains(176). This technique
may also be useful for Aβ imaging studies; however, further
studies are needed to validate this notion. The absorption and
bioavailability of curcumin is highly relevant, and the formulation,
dose and mode of delivery are each important factors. Multiple
over-the-counter brands are available, and most of them claim
increased bioavailability compared with unformulated curcumin;
however, independent comparative analysis is essential. Two
formulations BCM-95(177,178) and Longvida(145) currently have the
strongest independent data available in human trials. For a review
of the molecular structure of curcumin and its derivatives, FMeC1
and FMeC2, see Yanagisawa et al.(110), and differences between
the properties of CNB-001 can be examined as previously
published(179–181).
To summarise, curcumin has been trialled at doses as high as
8 g/d, and found to be well tolerated and safe. However, as new
formulations are emerging that are showing promise of
increasing bioavailability, BBB permeability and longer half-
lives, these formulations also need to be evaluated in future
safety and tolerability trials. Furthermore, as any curcumin
therapy is likely to be long-term in nature, much longer treat-
ment times need to be trialled. The animal and clinical studies
that have investigated the role of curcumin have applied a
variety of administration modes, including oral, subcutaneous,
intraperitoneal, intravenous, topical and the nasal route(182).
Human trials investigating curcumin’s neuroprotective
mechanisms have mostly used the oral route; however, future
studies should explore other routes of administration.
Curcumin as a fluorochrome/radioligand in Alzheimer’s
disease diagnosis
Turmeric has been used as a colouring agent since ancient times.
In 1989, Stockert et al.(183) identified curcumin as a potential
fluorochrome, as curcumin was found to fluoresce yellow/green
under a violet/blue (436 nm) light, and it was noted to bind to
DNA and chromosomes, as treatment of tissue samples and cell
samples with deoxyribonuclease or TCA prevented the chromatin
staining. More recently, these innate fluorescent qualities (curcu-
min absorbs light at about 420 nm and emits fluorescence at about
530 nm in aqueous solutions(184)), and curcumin’s natural affinity
to bind with Aβ, prompted curcumin to be tested as a safe plaque-
labelling fluorochrome. A mouse study investigated novel deri-
vatives of curcumin and measured their binding affinities for Aβ
aggregates(185). The derivative with the highest affinity was then
(18F)-radiolabelled for testing as a radioligand probe for Aβ plaque
imaging; the compound also had suitable lipophilicity, good brain
uptake and was metabolically stable in the brain. In another study
conducted on transgenic AD mice, multiphoton microscopy was
used to demonstrate that curcumin crossed the BBB and labelled
Aβ plaques and cerebrovascular amyloid angiopathy(40). Curcumin
has since been used in the labelling of neuronal fibrillar tau
inclusions in human brain samples of AD and progressive
supranuclear palsy(186). More recently, other studies of Aβ imaging
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used an 19F-containing curcumin derivative injected peripherally in
AD-model mice to detect Aβ plaques in the brains, using MRI(110).
Furthermore, Koronyo-Hamaoui et al.(187) demonstrated curcu-
min’s value as a staining agent for Aβ by detecting plaques in
human postmortem retinal tissue, and also as a brain and retinal Aβ
plaque tracer administered intravenously in transgenic mice.
Importantly, the pathology in the retina was detected before the
stage at which pathology in the brain could be detected, indicating
that curcumin may have potential as a pre-clinical AD biomarker.
The research also supports the previous observation that curcumin
has the ability to cross the BBB, which is essential for its therapeutic
efficacy. Preliminary data from a pilot study (n 40) conducted by
our group undertaking retinal imaging using curcumin as a
fluorochrome had a 100% sensitivity and 80·6% specificity for AD
diagnosis(3). Another study recruited mild cognitive impairment
(MCI) patients (n 30) and administered 80mg of curcumin (Meriva)
twice daily for 3 d and found abnormal deposits in different retinal
layers believed to be related to neurodegeneration(188). The study
reported that curcumin caused patchy hypofluorescent spots;
however, it did not quantify the retinal amyloid plaques. The
findings were primarily based on the direct perception of the
deposits via ocular imaging. Recent studies have again used
MRI, this time to detect magnetic nanoparticles made of
superparamagnetic iron oxide conjugated with curcumin, which
were found to bind to Aβ aggregates in ex vivo AD-model mouse
brains, after injection with the curcumin conjugate(189). Other
recent studies have produced a novel nanoimaging agent:
poly(β-L-malic acid) containing covalently attached (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) gadolinium and
curcumin. The all-in-one agent selectively binds to Aβ plaques and
can be detected by MRI(190), thus providing another promising Aβ
plaque imaging agent.
Curcumin, being non-toxic, accessible and economical, thus
becomes highly attractive for both diagnostics and therapeutic
research. As discussed above, retinal imaging using curcumin
fluorescence is currently being examined in our research centre as
part of the Australian Imaging, Biomarkers and Lifestyle flagship
study of ageing, and it has been found to be well tolerated by
participants. This approach, combined with examination of the
retinal vascular features(191), may deliver a novel diagnostic tool
that provides a more reliable indication of early AD changes, which
is economical, relatively non-invasive and widely applicable.
Limitations of curcumin and future directions
If all the positive results observed in in vitro and in vivo animal
studies could be translated into human studies, the significance
of curcumin in AD prevention and treatment would be
considerable. The recent study by Cox et al.(144) provided some
encouraging outcomes by investigating cognitive markers, but
only acute changes in attention, working memory and mood
were significant. No effects were reported in long-term memory
or executive function; however, the short duration of the study
may have been a limitation. The evidence that curcumin can
influence Aβ aggregation and Aβ clearance, support innate
immune systems, reduce oxidative stress, enhance cognition
and impede the onset of AD in humans remains elusive.
However, not to be overlooked is the application of curcumin
as a diagnostic fluorochrome, potentially assisting in the earlier
identification of pre-clinical stages of AD, during retinal
scanning. The use of curcumin as a fluorochrome within
retinal amyloid imaging, combined with examination of retinal
vascular features, offers a novel diagnostic approach to AD.
While retinal imaging is acknowledged as a non-invasive,
economical and easily translated technology, further validation
is required before it can be adopted as an early AD marker.
Enhanced oral formulations of curcumin are emerging,
potentially negating the prior challenges of absorption and
bioavailability. However, considering the differences in product
formulation, and the multitude of curcumin products already
available, comparative analysis would be useful. As the primary
focus of AD treatment has turned to primary prevention, the
point of intervention is also crucial: interventions introduced
early (>10 years before the onset of AD clinical symptoms) may
present difficulty establishing statistically significant changes,
whereas interventions introduced 1–2 years before the onset
may be less effective or ineffective as the disease pathology
may already be too advanced. Prevention studies designed with
longer duration are highly desirable; however, as nutraceuticals
generally do not attract commercial opportunity, realising these
type of studies will be difficult to accomplish.
The use of curcumin as an adjunct therapy to cholinesterase
inhibitors, particularly in the early stages of AD, offers a potentially
new area of research. As anxiety and stress are common
co-morbidities in AD, and research has shown curcumin to have
effect in these areas, curcumin may offer an appealing alternative
to antidepressant and antipsychotic therapies, while potentially
offering other synergies, including influencing the underlying
neuropathology and enhancing cholinergic activity. In recent
years, the focus on curcumin as a compound of interest for the
prevention of AD has been intensifying. The results of ongoing
clinical trials will hopefully shed more light on the benefits of
curcumin in the prevention of AD. In line with curcumin’s com-
plex modes of action, outcome measures should be expanded to
include not just cognitive changes; extensive blood biomarker
assays should also be carried out, as well as imaging (e.g.
measuring cerebral amyloid load and potentially retinal markers)
to characterise curcumin’s effects more fully over time, in a
pre-clinical population.
Conclusion
To date, AD clinical trials have not been able to generate the
anticipated benefits of curcumin; however, this has been
broadly attributed to difficulties with absorption, bioavailability
and arguably the timing and length of intervention. As reviewed
in this article, there is significant evidence that curcumin can act
on multiple pathways identified in the pathogenesis of AD. It is
possible, however, that sporadic AD in humans with the
associated cerebral atrophy and neuronal death may be less
responsive to curcumin than the AD induced in transgenic
animal models of the disease.
As discussed in this review, increasing the bioavailability, BBB
penetration and sustaining the half-life of curcumin remains a
major focus in relation to its dose–response. To achieve the same
degree of efficacy in human studies as compared with animal
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studies, closer scrutiny of the administration route and also
formulation are required, as increasing bioavailability and BBB
penetration is critical. Research analysing the different oral
formulations is lacking, and this is an area for further investigation.
Furthermore, as the pre-clinical signs of AD are present decades
before its clinical onset and most of the late-stage AD clinical trials
have recently failed, intervention must be focused at preventing
or delaying AD onset. It is reasonable to include healthy
community-dwelling older adults and those with subjective
memory complaints, in intervention studies with curcumin, for a
longer duration with longitudinal follow-up. Last, inclusion of
AD-related biomarkers and neuroimaging would add to the
clinical significance of curcumin’s efficacy in the prevention of AD
and associated cognitive decline.
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